LeslieSKeanMD
Pediatric Hematology & Oncology • Boston, MAAssociate Professor, Pediatrics, U of WA Sch of Med
Are you Dr. Kean?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Boston, MA 02115Phone+1 617-355-6000
Summary
- Dr. Leslie Kean, MD is a pediatric hematologist/oncologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts, Washington, and Georgia. She is an Associate Professor at U of WA Sch of Med.
Education & Training
Emory University School of MedicineClass of 1999
Certifications & Licensure
MA State Medical License 2018 - 2027
WA State Medical License 2013 - 2020
GA State Medical License 2003 - 2019
American Board of Pediatrics Pediatric Hematology-Oncology
Publications & Presentations
PubMed
- Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, Juan Wu, Carrie L Kitko
Journal of Clinical Oncology. 2025-03-10 - Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHD.Michael C Zaiken, Sujeong Jin, Cameron McDonald-Hyman, Christina Hartigan, Peter Sage
Blood. 2025-02-03 - The Adverse Event Landscape of Stem Cell Transplant: Evidence for AGVHD Driving Early Transplant Associated Toxicities.Takuto Takahashi, Benjamin Watkins, Brandi Bratrude, Donna Neuberg, Kyle Hebert
Transplantation and Cellular Therapy. 2025-02-01
Press Mentions
Dana-Farber Brigham Cancer Center Recognized for Exceptional Outcomes in Adult Donor Stem Cell Transplants for Fifth Consecutive YearJanuary 16th, 2025- Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS LymphomaDecember 13th, 2022
- Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Graft-Versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in AnimalsDecember 5th, 2022
- Join now to see all
Grant Support
- Novel Biologic Therapies for GVHDBOSTON CHILDREN'S HOSPITAL2010–2026
